ALNY · Company research

Alnylam Pharmaceuticals, Inc.

3 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

Trial resultsALNYAlnylamH2 2026

Alnylam expects to report results from its Phase 1 study of ALN-2232 for Obesity and weight management in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details

Entry

ALN-2232 Phase 1 obesity data · Clinical trial results (readout / topline data)

Drug

ALN-2232

For

Obesity and weight management

Stage

Phase 1 · an early safety study in a small group of people

When

H2 2026 · the company gave a window, not a day

Source note

Alnylam Q2 2026 press release guides Phase 1 results in the second half of 2026 — first clinical look at Alnylam's RNAi approach in obesity.

Checked

Checked by a person when it was added

Verify it

Source: investors.alnylam.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsALNYAlnylamH2 2026

Alnylam expects to report results from its Phase 1/2 study of ALN-6400 for Von Willebrand disease (bleeding disorders) in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.

More details

Entry

ALN-6400 Phase 1 (HV) and Phase 2 HHT results in 2H 2026 · Clinical trial results (readout / topline data)

Drug

ALN-6400

For

Von Willebrand disease (bleeding disorders)

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

H2 2026 · the company gave a window, not a day

Source note

existing entry ALNY|readout|2026-H2 'ALN-6400 Ph1/2 VWD' — Q2 2026 release specifies the 2H 2026 readouts are Phase 1 in healthy volunteers and Phase 2 in HHT; the VWD Phase 2 was only just initiated in Q2 2026.

Checked

Checked by a person when it was added

Verify it

Source: investors.alnylam.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

FDA decisionALNYAlnylamNov 2026

The FDA is expected to decide in Nov 2026 (no exact date yet) whether to approve Alnylam’s Cemdisiran for Generalized myasthenia gravis (anti-AChR+). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.

More details

Entry

PDUFA cemdisiran gMG (Regeneron-led; Alnylam royalty) · FDA decision due (PDUFA date)

Drug

Cemdisiran

For

Generalized myasthenia gravis (anti-AChR+)

Stage

NDA / Priority Review

When

Nov 2026 · the company gave a window, not a day

Source note

Alnylam July 30, 2026 Q2 release; same event as REGN|pdufa|2026-11 but attached to ALNY (Alnylam-discovered, Regeneron-led; EC decision anticipated H2 2027).

Checked

Checked by a person when it was added

Verify it

Source: investors.alnylam.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
Drugs@FDA ↗ — search the drug name for approval letters
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

MilestoneALNYAlnylamOct 26, 2026

Alnylam RNAi Roundtable on ALN-HTT02 (Huntington's), on Oct 26, 2026. A company milestone for Alnylam (ALN-HTT02 for Huntington's disease): a step in the program rather than a decision or a data readout.

More details

Entry

Alnylam RNAi Roundtable on ALN-HTT02 (Huntington's) · Company milestone

Drug

ALN-HTT02

For

Huntington's disease

Stage

Phase 1 · an early safety study in a small group of people

When

Oct 26, 2026

Source note

Roundtable webcast follows the planned Oct 23, 2026 EHDN presentation of initial Phase 1 ALN-HTT02 results.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsALNYAlnylamOct 23, 2026

Alnylam reported results from its Phase 1 study of ALN-HTT02 (RNAi targeting huntingtin) for Huntington's disease on Oct 23, 2026. The linked source has what the numbers showed.

More details

Entry

ALN-HTT02 Phase 1 initial results in Huntington's disease · Clinical trial results (readout / topline data)

Drug

ALN-HTT02 (RNAi targeting huntingtin)

For

Huntington's disease

Stage

Phase 1 · an early safety study in a small group of people

When

Oct 23, 2026

Source note

Alnylam Q2 2026 press release (July 30, 2026): initial Phase 1 results to be presented Friday, October 23, 2026 at the European Huntington's Disease Network Clinical Research Congress in Krakow.

Checked

Checked by a person when it was added

Verify it

Source: investors.alnylam.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneALNYAlnylamSep 17, 2026

Alnylam RNAi Roundtable on zilebesiran (hypertension), on Sep 17, 2026. A company milestone for Alnylam (Zilebesiran for Hypertension): a step in the program rather than a decision or a data readout.

More details

Entry

Alnylam RNAi Roundtable on zilebesiran (hypertension) · Company milestone

Drug

Zilebesiran

For

Hypertension

Stage

Phase 3 · the last stage before a drug can be approved

When

Sep 17, 2026

Source note

June 12, 2026 PR announcing the tenth RNAi Roundtable series; zilebesiran session 'Targeting Angiotensinogen to Achieve Continuous Control of Blood Pressure' webcast Sept 17, 2026.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceALNYAlnylamJul 15, 2026

Alnylam presented data on Mivelsiran (ALN-APP); ALN-5288 for Cerebral amyloid angiopathy and Alzheimer's disease at a medical meeting on Jul 15, 2026. The linked source has the details.

More details

Entry

Mivelsiran Phase 1 EOAD data and Phase 2 Down syndrome study start at AAIC · Data presented at a medical meeting

Drug

Mivelsiran (ALN-APP); ALN-5288

For

Cerebral amyloid angiopathy and Alzheimer's disease

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

Jul 15, 2026

Source note

At AAIC 2026 Alnylam presented updated Phase 1 mivelsiran data in early-onset Alzheimer's disease showing low ARIA incidence, announced initiation of the global Phase 2 APPlauDS study in Down syndrome-associated Alzheimer's, and shared preclinical data for tau-targeting ALN-5288.

Checked

Checked by a person when it was added

Verify it

Source: investors.alnylam.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceALNYAlnylamMay 12, 2026

Alnylam presented data on Vutrisiran (AMVUTTRA) for ATTR amyloidosis with cardiomyopathy at a medical meeting on May 12, 2026. The linked source has the details.

More details

Entry

HELIOS-B analyses at Heart Failure 2026 show consistent vutrisiran benefit · Data presented at a medical meeting

Drug

Vutrisiran (AMVUTTRA)

For

ATTR amyloidosis with cardiomyopathy

Stage

Phase 3 · the last stage before a drug can be approved

When

May 12, 2026

Source note

At the Heart Failure Association of the ESC congress, Alnylam presented new HELIOS-B Phase 3 analyses showing consistent clinical benefit across ATTR-CM subgroups including high disease burden, plus pooled safety across more than 25,000 patient-years of TTR-silencing RNAi experience.

Checked

Checked by a person when it was added

Verify it

Source: investors.alnylam.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceALNYAlnylamMar 30, 2026

Alnylam presented data on Vutrisiran (AMVUTTRA); zilebesiran for ATTR amyloidosis with cardiomyopathy; hypertension at a medical meeting on Mar 30, 2026. The linked source has the details.

More details

Entry

Vutrisiran HELIOS-B and zilebesiran data presented at ACC.26 · Data presented at a medical meeting

Drug

Vutrisiran (AMVUTTRA); zilebesiran

For

ATTR amyloidosis with cardiomyopathy; hypertension

Stage

Phase 3 · the last stage before a drug can be approved

When

Mar 30, 2026

Source note

Alnylam presented new HELIOS-B Phase 3 analyses showing vutrisiran improved how ATTR-CM patients feel and function, plus real-world adherence data and pooled Phase 2 safety data for zilebesiran in hypertension, at the American College of Cardiology Annual Scientific Session.

Checked

Checked by a person when it was added

Verify it

Source: investors.alnylam.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsALNYAlnylamJun 24, 2024

Alnylam reported results from its Phase 3 study of vutrisiran (Amvuttra) for ATTR cardiomyopathy on Jun 24, 2024. The linked source has what the numbers showed.

More details

Entry

HELIOS-B topline: vutrisiran hit all endpoints · Clinical trial results (readout / topline data)

Drug

vutrisiran (Amvuttra)

For

ATTR cardiomyopathy

Stage

Phase 3 · the last stage before a drug can be approved

When

Jun 24, 2024

Source note

Phase 3 in ATTR cardiomyopathy: the readout that re-rated the stock.

Checked

Checked by a person when it was added

Verify it

SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
ALNY headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to ALNY.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.